Save on Lumakras with Coupons, Discounts & Savings Programs

Lumakras is the brand name for sotorasib oral tablets.

Lumakras is available as a 120 mg and 320 mg oral tablet.

Lumakras is a KRAS G12C inhibitor and is used to treat metastatic non-small cell lung cancer (NSCLC) with a KRAS G12C mutation, after having tried at least one previous cancer treatment.

Lumakras is a KRAS G12C inhibitor. KRAS is a protein in your body that sends signals to your cells to grow and divide. In certain lung cancers, a mutation (change) in KRAS called G12C leads to uncontrolled cell growth. Lumakras attaches to KRAS proteins with the G12C mutation. By doing so, the medication helps block tumor growth.

The typical dose is 960 mg by mouth once a day, with or without food. Lumakras is available as 120 mg and 320 mg tablets. The daily dose is taken as eight 120 mg tablets or three 320 mg tablets at one time each day.

Lumakras is a safe and effective treatment when used for FDA licensed indications. However, like all medications, they may give you unwanted side effects. You should always discuss potential side effects with your physician to ensure the medication is suitable and right for you.

Common side effects of Lumakras:

• Diarrhea
• Muscle or bone pain
• Fatigue
• Nausea
• Cough

Serious side effects are rare with Lumakras. Contact your healthcare provider immediately if you experience any of the following.

• Liver injury: pain in the right side of the stomach, yellowing of the eyes or skin, dark or brown urine
• Lung damage: cough, shortness of breath, fever

The following medications may interact with Lumakras:

• Coadministration of Lumakras with gastric acid-reducing agents decreased sotorasib concentrations which may reduce the efficacy of sotorasib. Avoid coadministration of Lumakras with proton pump inhibitors (PPIs), H2 receptor antagonists, and locally acting antacids. If coadministration with an acid-reducing agent cannot be avoided, administer Lumakras 4 hours before or 10 hours after administration of a locally acting antacid

Lumakras is a CYP3A4 substrate. Coadministration of Lumakras with a strong CYP3A4 inducer decreased

• sotorasib concentrations , which may reduce the efficacy of sotorasib. Avoid coadministration of Lumakras with strong CYP3A4 inducers

Sotorasib is a P-gp inhibitor. Coadministration of Lumakras with a P-gp substrate increased its plasmaconcentrations, which may increase the adverse reactions of the substrate. Avoid coadministration of Lumakras with P-gp substrates, for which minimal concentration changes may lead to serious toxicities. If coadministration cannot be avoided, decrease the P-gp substrate dosage in accordance with its Prescribing Information.

Sotorasib is a BCRP-inhibitor. Coadministration of Lumakras with a BCRP substrate increased its plasma

• concentrations, which may increase the risk of adverse reactions of the substrate. When coadministered with Lumakras, monitor for adverse reactions of the BCRP substrate and decrease the BCRP substrate dosage in accordance with its Prescribing Information

Amgen Inc.

It is not known if Lumakras may harm your unborn baby. Talk to your healthcare provider about possible pregnancy and birth control choices that are right for you.

• Sotorasib